A very recent study reported a lower risk of adverse clinical events in patients with IBD and T2D treated with GLP-1R agonists/DPP-4 inhibitors, suggesting the effectiveness of GLP-1 based therapies as treatment for comorbidity of the two diseases [62]. This evidence concerns the gene GLP1R and inflammatory bowel disease.